Association of compounded bevacizumab with postinjection endophthalmitis

JAMA Ophthalmology

Volumn 133, Issue 10, 2015, Pages 1159-1164

  VanderBeek, Brian L ^a,b   Bonaffini, Sarah G ^c   Ma, Liyuan ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; COHORT ANALYSIS; DATA ANALYSIS; DATA COLLECTION METHOD; ENDOPHTHALMITIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED STATES; ADVERSE EFFECTS; CHEMISTRY; DRUG FORMULATION; DRUG LEGISLATION; DRUG PACKAGING; EYE INFECTIONS, BACTERIAL; FACTUAL DATABASE; INTRAVITREAL DRUG ADMINISTRATION; ODDS RATIO; RETINAL DISEASES; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DATABASES, FACTUAL; DRUG COMPOUNDING; DRUG PACKAGING; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; LEGISLATION, DRUG; MALE; ODDS RATIO; RETINAL DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84943638788     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2015.2556     Document Type: Article

References (21)

1. Elman MJ, Qin H, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119 (11):2312-2318.
2. Martin DF, Maguire MG, Fine SL, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
3. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4): 789-801.
4. Ogura Y, Roider J, Korobelnik JF, et al; GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014;158(5):1032-1038.
5. Corbett-Corren J. FDA warns on eye infections with repacked Avastin.Wall Street Journal. August 31, 2011. http://www.wsj.com/articles/SB10001424053111904716604576542233203196792. Accessed May 4, 2015.
6. Repackaged Avastin caused eye infections in Florida. Reuters. August 31, 2011. http://www.reuters.com/article/2011/08/31/avastin-infection-idUSN1E77U08E20110831. Accessed May 4, 2015.
7. Pollack A. Avastin injections are reported to cause blindness. New York Times. August 31, 2011;§B3. http://www.nytimes.com/2011/08/31/health/31drug.html?-r=0. Accessed May 4, 2015.
8. Pollack A. Five more reports of Avastin injections causing blindness. New York Times. September 2, 2011;§B2. http://www.nytimes.com/2011/09/02/business/more-reports-of-avastin-causing-blindness.html. Accessed May 4, 2015.
9. Goldberg RA, Flynn HW Jr, Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):204-208.e1. doi:10.1016/j.ajo.2011.11.035.
10. Frost BA, Kainer MA. Safe preparation and administration of intravitreal bevacizumab injections [comment]. N Engl J Med. 2011;365(23): 2238.
11. Pharmaceutical Quality, Security, and Accountability Act, S 959, 113th Congress (2013-2104). http://www.congress.gov/bill/113th-congress/senate-bill/959. Accessed May 6, 2015.
12. US Department of Health and Human Services, Food and Drug Administration. Mixing, diluting, or repackaging biological products outside the scope of an approved biologics license application. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm434176.pdf. Accessed May 5, 2015.
13. American Academy of Ophthalmology. Tell FDA compounding regulation would interfere with AMD and other treatment options. http://www.aao.org/eye-on-advocacy-article/tell-fda-compounding-regulation-would-interfere-wi. Accessed April 28, 2015.
14. Emerson G. American Society of Retina Specialists' Comments: FDA Drug Compounding Listening Session 4/30/15. https://www.asrs.org/advocacy-practice/access-to-safe-compounded-agents. Accessed April 30, 2015.
15. Nentwich MM, Yactayo-Miranda Y, Schwarzbach F, Wolf A, Kampik A, Mino de Kaspar H. Endophthalmitis after intravitreal injection: decreasing incidence and clinical outcome: 8-year results from a tertiary ophthalmic referral center. Retina. 2014;34(5):943-950.
16. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011;31(4):662-668.
17. Flynn HW, Gregori N, Moashfeghi AA, et al. Current endophthalmitis incidence rates after intravitreal anti-VEGF injections and outcomes of treatment [abstract 4193-C0076]. Poster presented at: 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology; May 5, 2015; Denver, CO.
18. Lima LH, Zweifel SA, EngelbertM, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina. 2009;29(9):1213-1217.
19. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145(5):879-882.
20. Sharma S, Johnson D, Abouammoh M, Hollands S, Brissette A. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012;47(3):275-279.
21. Orozco-Hernández A, Ortega-Larrocea X, Sánchez-Bermúdez G, García-Aguirre G, Cantón VM, Velez-Montoya R. Acute sterile endophthalmitis following intravitreal bevacizumab: case series. Clin Ophthalmol. 2014;8: 1793-1799.